Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Weight reduction and body fat reduction applications of chitosan oligosaccharide

A technology of chitosan oligosaccharide and number average molecular weight, applied in the field of medicine, can solve problems such as influence on the popularization and application of chitosan oligosaccharide, unclear application mechanism, unstable application effect, etc.

Active Publication Date: 2013-09-25
GUANGDONG PHARMA UNIV
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have found that chitosan oligosaccharides have certain effects on neuroprotection, anti-tumor, antibacterial, anti-inflammatory, hypoglycemic, anti-oxidation, liver protection, etc. Further promote the application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Weight reduction and body fat reduction applications of chitosan oligosaccharide
  • Weight reduction and body fat reduction applications of chitosan oligosaccharide
  • Weight reduction and body fat reduction applications of chitosan oligosaccharide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] 1 Materials and methods

[0033] 1.1 Test samples

[0034] Chitooligosaccharides (Shandong Laizhou Haili Biological Products Co., Ltd., COS1 number average molecular weight ≤ 1000, production batch number HL120916G; COS2 number average molecular weight ≤ 3000, production batch number HL120911G; COS3 number average molecular weight ≤ 5000, production batch number HL120907G).

[0035] 1.2 Experimental animals

[0036] 185 male Sprague Dawley rats of SPF grade (permit number: SCXK (Guangdong) 2008-0002), weighing 70-90 g, were purchased from Guangdong Medical Experimental Animal Center, and were fed adaptively for one week.

[0037] 1.3 Reagents and Instruments

[0038] Orlistat Capsules (Chongqing Huasen Pharmaceutical Co., Ltd.); Alanine Aminotransferase Assay Kit (ALT), Aspartate Aminotransferase Assay Kit (AST), Triglyceride Assay Kit (TG) , total cholesterol assay kit (CHO), high-density lipoprotein cholesterol assay kit (HDL-C), low-density lipoprotein cho...

Embodiment 2

[0125] Embodiment 2 toxicity test

[0126] 1 Pre-experiment

[0127] SPF-grade NIH mice, weighing 18-22 g, half male and half male, were reared in separate cages, fed adaptively for 3 days in an environment with a temperature of 22±1°C and a relative humidity of 50-60%, with free access to food and drinking water. limit. In the experiment, the maximum concentration of COS1 and COS2 described in Example 1 (the drug just passed through the gavage needle smoothly, and the physical and chemical properties did not change) was used to gavage the mice, and the pre-experiment set up 3 dosage groups, respectively 16g / Kg (Give once), 32g / Kg (Give twice), 48g / Kg (Give three times), each dose group has 10 mice, half male and half male. Before administration, fast for 16 hours, without restriction on drinking water, the volume of each administration is 0.2mL / 10g, and the interval between each administration is 5h.

[0128] COS1 pre-test results:

[0129] 1.16g / Kg dose: the mice had...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, particularly to applications of chitosan oligosaccharide. According to the present invention, chitosan oligosaccharide is applied in preparation of drugs with functions of weight reduction and / or body fat reduction, and chitosan oligosaccharide with a number average molecular weight of not more than 3000 is preferably selected, wherein the chitosan oligosaccharide with different number average molecular weights provides significant application effects in body weight control, body fat ratio reduction, and reduction of total cholesterol and / or low density lipoprotein cholesterol in blood serum. In addition, the chitosan oligosaccharide has effects of weight reduction, body fat reduction, fatty liver alleviating and reduction of blood fat in blood serum.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an application of chitosan oligosaccharide for weight loss and lipid reduction. Background technique [0002] Obesity is a chronic nutritional disease caused by the imbalance of energy metabolism in the body. Looking around the world, the number of obese people is increasing in every country. 66% of American adults are overweight or obese, and the prevalence of obesity is 32%. In China, as of 2009, the proportion of obesity in men has reached 11.4%, that of women has reached 10.1%, the proportion of abdominal obesity in men is 27.8%, and that of women is 45.9%. Studies have shown that obesity can be caused by multiple factors such as genes, diet, environment, traditions, etc. It is caused by non-alcoholic fatty liver disease (NAFLD), type Ⅱ diabetes, atherosclerosis (AS), tumors, sleep disorders, osteoarthritis, etc. predisposing factors for disease. Therefore, finding safe ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/722A61P3/04A61P3/06
Inventor 苏政权陈健黄贵东潘海涛丁晨谭思荣
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com